The clinical and pathological features, biomarker characteristics and prognosis analysis of lung adenosquamous carcinoma
10.3760/cma.j.issn.0253-3766.2019.01.014
- VernacularTitle:肺腺鳞癌的临床病理和分子生物学特征及其预后影响因素分析
- Author:
Shengyu ZHOU
1
;
Qi XUE
;
Jianming YING
;
Xingsheng HU
;
Jianliang YANG
;
Hua LIN
;
Yuankai SHI
Author Information
1. 国家癌症中心国家肿瘤临床医学研究中心中国医学科学院北京协和医学院肿瘤医院肿瘤内科抗肿瘤分子靶向药物临床研究北京市重点实验室100021
- Keywords:
Lung adenosquamous carcinoma;
Drive mutation;
EGFR;
Prognosis
- From:
Chinese Journal of Oncology
2019;41(1):50-55
- CountryChina
- Language:Chinese
-
Abstract:
Objective Adenosquamous carcinoma of lung is an uncommon subtype with more aggressive behavior and poor prognosis than adenocarcinoma and squamous cell carcinoma. This study was aimed to investigate the clinicopathological characteristics and prognostic factors of lung adenosquamous carcinoma. Methods The pathological features and follow?up data of 133 patients were collected and the prognostic factors of these patients were retrospectively analyzed.Results Among the 133 patients, 81 cases (60.9%) smoked. Among the 62 patients whose percentage of histological components were identified, 45 cases had ＞ 50% adenocarcinoma components, and 17 cases had ＞ 50% squamous cell carcinoma components. 55 patients had lymph node metastasis at the first visit. All patients accepted at least one test of tumor driven gene mutation, and the results showed that the mutation rate of EGFR was 50.8%(67／132), the mutation rate of K?ras was 8.6%( 11／128), the ALK?positive rate was 4.2%(2／48). The gender, smoking status, and the proportion of pathological components were the main influence factors of EGFR mutation status. The median overall survival was 28 months, the rates of 1?year, 3?year, and 5?year survival were 72.9%, 23.3%, and 9.0%, respectively. EGFR tyrosine kinase inhibitors ( TKIs) treatment was an independent risk factor for prognose of these patients ( P ＝ 0. 024 ). Conclusions Lung adenosquamous carcinoma is a rare subtype with high malignancy and poor prognosis. Early diagnosis and driven?mutation?based individualized therapy may improve the survival of patients with lung adenosquamous carcinoma.
